circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis.

"Declarations Ethics approval and consent to participateThe current study was approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University. All patients signed informed consent before biopsy or surgery. The animal experiments were approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This work was supported by The National Natural Science Foundation of China (81871894), the Clinical Research and Innovation Team Support Program of Hebei Medical University (2022LCTD-A11), the Graduate Innovation Foundation of Hebei Province, China (No. CXZZBS2022093) and the Medical Science Research Program of Hebei Health Commission (20230906 & 20240427)."